Cetuximab could diminish TXNDC5 expression, thereby augmenting the generation of ROS and developing the endoplasmic reticulum stress-related apoptosis of laryngeal squamous cell carcinoma cells [40]. This evidence concerns the gene TXNDC5 and laryngeal squamous cell carcinoma.